The proposed $18 bln merger of healthcare data miner IMS and drug-trial manager Quintiles may save costs but lacks clear logic. Robert Cyran and Reynolds Holding pick through the de
from Reuters Video: Breakingviews http://ift.tt/1TjizHI
via IFTTT
No comments:
Post a Comment